Cardiac Biomarker Analyzer

A comprehensive menu of lab-quality urgent cardiac tests

High throughput, fast turnaround, and exceptional ease of use

Can run up to 6 whole blood or plasma assays on one patient sample at a time

Easy LIS integration and compact benchtop footprint

Troponin I testing: Lab-quality troponin with high analytical precision in minutes

<17 minutes

6% CV at the 99th percentile cutoff of 0.029 ng/ML in under 17 minutes1

Most precise
point of care Troponin I

Based on the latest guidelines, this level of precision enables the use of accelerated diagnostic protocols to optimize patient care and throughput.2

NTproBNP testing: Answers in minutes at the point of care

Gold-standard therapy monitoring for patients with heart failure

Gold-standard therapy monitoring for patients with heart failure. For patients receiving treatment with sacubitril/valsartan (ENTRESTO®), NTproBNP is the preferred and recommended biomarker for assessing risk of cardiovascular death or hospitalization for heart failure (HF).3

For Hospitals

  • In the ED: Rapid NTproBNP results inform risk stratification and admission decisions4
  • During hospitalization: NTproBNP informs in-hospital management of patients admitted with decompensated CHF5,6 or severe COVID-197
  • Prior to discharge: NTproBNP levels can help inform patient prognosis8

For Heart Failure Clinics

  • Improve the patient experience: With on-site testing, fragile heart failure patients get the highest quality and most efficient care possible
  • Optimize clinic efficiency and drive revenue: HF clinicians can make immediate treatment decisions with less need for follow up and practices can bill for diagnostic services that would otherwise be sent to an outside lab
Instrument type Bench-top Cardiac Biomarker Analyzer
Throughput Up to 6 samples or assays per run
Measuring time <17 minutes for to up to six simultaneous samples
Sampling material Whole blood, plasma
Measuring principle Chemiluminescence enzyme immunoassay technology (CLEIA) combined with proprietary Magtration™ technology
Reaction temperature 37.5° C
Sample volume 100 µL
Wavelength 300-650 nm
Data storage Patient data: 1000
QC data 1800
CAL data 300
Data transfer ASTM standard
Dimensions 13.5 in. W x 22.4 in. D x 18.7 in. H
Weight 62 lbs
Electrical requirements 100-240 Vac
Monitor/keyboard LCD Touchscreen
Printer/PC Integrated
Interface RS-232C
Calibration Factory calibration, 2-point calibration every 4 weeks
24-h operation (standby)

Ordering information

Contact us

Connect with us

Fill out the form to submit your information.


  1. Point of care cardiac troponin I and T assay analytical characteristics. IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Accessed June 23, 2023.
  2. AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR, Gulati M, Levy PD, et al. Guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e455. doi:10.1161/CIR.0000000000001047
  3. McKie PM, Burnett JC Jr. NT-proBNP: The gold standard biomarker in heart failure. J Am Coll Cardiol. 2016;68(22):2437-2439. doi:10.1016/j.jacc.2016.10.001
  4. Cardiac biomarkers and heart failure. American College of Cardiology. May 5, 2023. Accessed August 24, 2023.
  5. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7(1):21-29. doi:10.1054/jcaf.2001.23355
  6. Amerena PJ, Vathesatogkit DP, Kaul PU, et al. NT-proBNP in Hospital & Ambulatory Settings: Evidence to clinical practice. Cardio Think Lab. September 17, 2020. Accessed August 24, 2023.
  7. Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83. doi:10.1186/s12931-020-01352-w
  8. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 202;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012